4-(6-OXO-3-(4'-CHLOROPHENYL)-5,6-DIHYDROPYRIDAZIN-1(4H)-YL)-N-(PHENYLCARBAMOTHIOYL)BENZENESULFONAMIDE


Molecule Category	Free-form
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	GMAKMXLHCDDFIA-UHFFFAOYSA-N
Smiles	Clc1ccc(cc1)C2=NN(C(=O)CC2)c3ccc(cc3)S(=O)(=O)NC(=S)Nc4ccccc4
InChI	InChI=1S/C23H19ClN4O3S2/c24-17-8-6-16(7-9-17)21-14-15-22(29)28(26-21)19-10-12-20(13-11-19)33(30,31)27-23(32)25-18-4-2-1-3-5-18/h1-13H,14-15H2,(H2,25,27,32)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C23H19ClN4O3S2
Molecular Weight	499.0
AlogP	5.14
Hydrogen Bond Acceptor	5.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	7.0
Polar Surface Area	131.34
Molecular species	ACID
Aromatic Rings	3.0
Heavy Atoms	33.0

Assay Description	Organism	Bioactivity	Reference
Antihyperglycemic activity in Rattus norvegicus Wistar albino (rat) assessed as blood glucose level at 20 mg/kg, po administered 30 min before 3 g/kg, po glucose challenge by oral glucose tolerance test (Rvb = 149 +/- 6.3 mg/dl)	Rattus norvegicus	148.0 mg/dl
Antihyperglycemic activity in Rattus norvegicus Wistar albino (rat) assessed as reduction in blood glucose level at 20 mg/kg, po administered 30 min before 3 g/kg, po glucose challenge by oral glucose tolerance test	Rattus norvegicus	4.7 %

Cross References

Resources	Reference
ChEMBL	CHEMBL2235655
PubChem	76318868

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).